REYKJAVIK, Iceland, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the completion of a private placement of approximately $137 million, at current

REYKJAVIK, Iceland and TOKYO, Jan. 13, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Japanese pharmaceutical company Fuji Pharma Co., Ltd.

REYKJAVIK, Iceland, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the initiation of a pharmacokinetic study for AVT05, a biosimilar candidate to

The U.S. Food and Drug Administration’s (FDA) regulatory review is anticipated to be completed in the second half of 2023 Stelara ® (ustekinumab) is prescribed to treat a variety of inflammatory conditions REYKJAVIK, Iceland and PARSIPPANY, N.J., Jan.

U.S. Food and Drug Administration (FDA) has confirmed that the goal date for an approval decision on Alvotech’s license application for AVT02 is April 13, 2023 FDA has completed review of Alvotech’s application of AVT02 as an interchangeable to high-concentration of Humira ®  and confirmed that the

Alvotech announces the completion of a private placement of approximately US$70 million, at current exchange rates, of subordinated convertible bonds. Alvotech intends to use the majority of the net proceeds from the private placement offering to replace a US$50 million unsecured subordinated loan from Alvogen.

Robert Wessman Founder and Executive Chairman will ring the Nasdaq Iceland closing bell at 15:30 GMT on December 8, 2022 Listing on the Main Market can increase visibility, which may allow the company to appear in both domestic and global indexes Alvotech became first dual-listed Icelandic company

Reference is made to the announcement issued on December 2, 2022 confirming that Nasdaq Iceland has approved Alvotech S.A’s (“Alvotech”) request for admission to trading of its shares on the Nasdaq Iceland Main Market (“Main Market”), pending passporting of the prospectus to Iceland.

Nasdaq Iceland has approved Alvotech S.A’s (“Alvotech”) request for admission to trading of its shares on the Nasdaq Iceland Main Market (“Main Market”). Alvotech’s shares will be admitted to trading on the Main Market following the passporting of Alvotech’s prospectus to Iceland.